The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels
NCT ID: NCT00167882
Last Updated: 2006-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
24 participants
INTERVENTIONAL
2005-07-31
2006-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The concomitant use of 5-aminosalicylates (5ASA) next to azathioprine (AZA) or 6-mercaptopurine (6MP) in the treatment of inflammatory bowel disease (IBD) may lead to an increased effectiveness of therapy as higher levels of the active metabolite of AZA/6MP (6-thioguaninenucleotides (6TGNs) are measured.
Objectives:
To determine the influence of 5-ASA compounds and its metabolites on the metabolites of AZA/6MP (6TGNs + 6-methylmercaptopurine (6MMP).
Methods:
Patients with quiescent disease under AZA/6MP therapy are eligible. Patients will receive three succeeding regimes (5ASA 2 gram/5ASA 4 gram/ no 5ASA) of 4 weeks next to the standard AZA/6MP therapy. At the start and at the end of every regime 5ASA and its major metabolite (N-acetyl-5ASA) will be determined in serum next to the measurement of 6TGNs and 6MMP in erythrocytes. The safety will monitored by standard laboratory parameters every four weeks.
Population:
Patients with IBD in remission and unchanged AZA/6MP dosages for at least 4 weeks.
Medication:
5ASA (Pentasa ® granules; Ferring) will be administered orally in dosages of 2 or 4 grams daily for a period of 4 weeks.
Endpoints:
The rise or decrease in 6TGNs and 6MMP during the different 5ASA regimes. The evaluation of the safety of co-administrating 5ASA next to AZA/6MP.
Risks:
Side effects of 5ASA use are limited and well known. Some case reports have described the potential risk of developing a myelodepression when AZA/6MP and 5ASA are given together due to the rise in 6TGNs. However, in daily practice both drugs are administered together frequently. The risks of the frequent blood draws are minimal and usually self-limiting (haematoma).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
5-aminosalicylate (Pentasa, Ferring)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent
* Diagnosis of CD or UC for at least 6 months (histological and endoscopically confirmed)
* Steady state AZA of 6-MP use (an unchanged thiopurine regime for at least 4 weeks)
* Normal liver and kidney function (ALAT / AP / creatinin \< 2 x upper normal limit)
* Quiescent disease (HBI score ≤ 4 for CD or modified TLWI score ≤ 4 for UC)
Exclusion Criteria
* Presence of active infection (fever and CRP \> 1 x upper normal limit)
* Anemia (hemoglobin \< 6 mmol)
* Known duodenal Crohn's disease interfering significantly with resorptive area
* Small bowel surgery interfering significantly with resorptive area
* Known intolerance to 5-ASA compounds
* Current use of 5-ASA compounds
* Use of 5-ASA compounds within the last 30 days
* Concomitant use of allopurinol, ACE-inhibitors or furosemide
* Pregnancy, expected pregnancy or lactation within 6 months
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amsterdam UMC, location VUmc
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
K.H.N. de Boer, MD
Role: PRINCIPAL_INVESTIGATOR
Amsterdam UMC, location VUmc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maasland Hospital
Sittard, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004 Jun;26(3):311-8. doi: 10.1097/00007691-200406000-00016.
de Boer NK, de Graaf P, Wilhelm AJ, Mulder CJ, van Bodegraven AA. On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment. Aliment Pharmacol Ther. 2005 Sep 1;22(5):447-51. doi: 10.1111/j.1365-2036.2005.02581.x.
Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis. 2005 Apr;37(4):282-97. doi: 10.1016/j.dld.2004.09.029.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005/28
Identifier Type: -
Identifier Source: org_study_id